Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.37 |
| ▸ | PPARA | Q07869 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | GFER | P55789 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13408005 | 0.89 | PPARG (0.42) | PPARGPPARAMEN1HTTKMT2A | |
| SCHEMBL14291346 | 0.85 | RAB9A (0.39) | MEN1HTTKMT2AGFERHSD17B10 | |
| SCHEMBL10024349 | 0.82 | PPARG (0.35) | PPARGPPARAFFAR4 | |
| SCHEMBL3095728 | 0.76 | PPARG (0.46) | PPARGPPARAMEN1KMT2AFFAR4 | |
| SCHEMBL3095738 | 0.76 | PPARG (0.46) | PPARGPPARAMEN1KMT2AFFAR4 | |
| SCHEMBL1610643 | 0.75 | PPARG (0.45) | PPARGPPARAMEN1KMT2AFFAR4 | |
| SCHEMBL19917508 | 0.72 | ALDH1A1 (0.47) | MEN1HTTKMT2AGFERHSD17B10 | |
| SCHEMBL3518571 | 0.71 | KDM6B (0.39) | PPARGPPARAFFAR1FFAR4KDM4E | |
| SCHEMBL3518576 | 0.71 | KDM6B (0.39) | PPARGPPARAFFAR1FFAR4KDM4E | |
| SCHEMBL2088199 | 0.71 | PTGER4 (0.44) | PPARGPPARAMEN1KMT2AFFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119797-B2 | Production method | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-21 | — | — | US | disclosed |
| US-8119797-B2 | Production method | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-21 | — | — | US | disclosed |
| US-8084634-B2 | Production method | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-27 | — | — | US | disclosed |
| US-8084634-B2 | Production method | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-27 | — | — | US | disclosed |
| US-20110295000-A1 | PRODUCTION METHOD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20110295000-A1 | PRODUCTION METHOD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-01 | — | — | US | disclosed |
| US-20100152439-A1 | PRODUCTION METHOD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-17 | — | — | US | disclosed |
| US-20100152439-A1 | PRODUCTION METHOD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110295000-A1 | PRODUCTION METHOD | CYP2F1, CYP7A1, CYP1A1 | PPARG 2179/4885PPARA 3347/4885MEN1 307/4885 |
| US-20100152439-A1 | PRODUCTION METHOD | CYP2F1, CYP7A1, CYP1A1 | PPARG 2179/4885PPARA 3347/4885MEN1 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.